Softwr

Healthcare · head to head

Annalise.ai vs Rx30

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Rx30 logo

Rx30

Healthcare

Long-established pharmacy management system for independents and small chains

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Rx30 covers Prescription processing.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Rx30 actually diverge.

Attributes where Annalise.ai and Rx30 differ
AttributeAnnalise.aiRx30
PlatformsWeb, Cloud, On-premiseWindows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Rx30

  • Prescription processing
  • Claims adjudication
  • Inventory and purchasing
  • Point of sale
  • Delivery management
  • Clinical documentation

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Rx30
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Rx30
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Rx30
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Rx30

Rx30

  • Independent pharmacies and small chains wanting a mature, widely-supported systemnot Annalise.ai
  • Operations relying on a broad set of wholesaler and PBM interfacesnot Annalise.ai
  • Pharmacies with significant front-end retail alongside dispensingnot Annalise.ai
  • Multi-store independents needing consistency across locationsnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Rx30

  • Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • The interface shows its age against newer entrants, and this is the most common objection in demonstrations
  • Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
  • Windows-centric, with a cloud story less developed than newer competitors
  • US-only, tied to US insurance and regulatory requirements

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Rx30

On request
  • Rx30$undefined/month
    • Prescription processing
    • Claims adjudication
    • Inventory

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Rx30 if

  • You need prescription processing.
  • You work on Windows, Web.
  • You also want claims adjudication.
Rx30 review

Questions people ask

Is Annalise.ai or Rx30 better?
Neither clearly leads. Annalise.ai starts at On request and Rx30 at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Rx30?
Annalise.ai starts at On request and Rx30 at On request.
Does Annalise.ai or Rx30 run on more platforms?
Annalise.ai runs on Web, Cloud, On-premise. Rx30 runs on Windows, Web.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Rx30 is typically brought in for.
What can Annalise.ai do that Rx30 cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Rx30: Is Rx30 the same company as PioneerRx?

Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.

Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Rx30: What does it cost?

Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Rx30: Why do pharmacies stay on it?

Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Rx30: How does it compare to PioneerRx?

PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.

Rx30: Is it suitable for a small chain?

Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.

Share

Related pages

More on Annalise.ai

More on Rx30

Keep looking

Other head to heads